July 6, 2005: TORONTO, CANADA: VisualSonics has introduced the next generation of its micro-imaging platform - - the Vevo 770™ high-resolution in vivo imaging system for small animal research. “We are very excited to introduce the Vevo 770 to the small animal imaging marketplace”, said Tom Little, CEO of VisualSonics. “This platform provides our growing customer base with the same benefits of our Vevo 660 - - real time quantifiable imaging of small animal models in vivo - - but now with added functionality, image quality, and capabilities for new applications”.
VisualSonics has installations at the top academic institutions and pharmaceutical and biotechnology companies in North America, Europe, Japan and across Asia. With the Vevo 770™ platform, image quality has been significantly improved providing the small animal researcher with greater insights into early development of phenotypes and responses to therapeutics in vivo. “The functionality inherent in the new Vevo platform - - especially Power Doppler - - makes micro-ultrasound even more useful for the longitudinal studies we are performing in our mouse models of prostate and liver cancer”, says Dr. Aaron Fenster, Director of Imaging Research, Robarts Research Institute (London, ON) and a long-time customer and collaborator of VisualSonics. “This new platform continues to expand both the functionality and image quality of the Vevo and therefore leverages the strengths of this modality for small animal imaging”.
In addition, the redesigned platform provides improvements in frame rates, ergonomics and most, important, expanded capacity allowing for new applications in cancer research such as the quantification of microvasculature in tumors for anti-angiogenic research and drug development.
About VisualSonics
VisualSonics Inc. (http://visualsonics.com/) is the leading manufacturer of high-resolution in vivo imaging systems for small animal research. VisualSonics’ Vevo 770™ high-resolution imaging system provides real-time visualization and measurement of anatomical and hemodynamic function in small animals down to 30 microns. Because of the non-invasive nature of the technology, longitudinal studies of the same animal can be performed. This high-resolution imaging technology is being successfully applied to phenotypic-based research applications such as developmental biology, cardiovascular research, cancer biology, neurobiology and preclinical drug discovery.
About Robarts Research Institute
Robarts Research Institute (www.robarts.ca) is Canada's independent medical research institute. Its scientists are international leaders harnessing the power of cell biology, genomics and advanced medical imaging technologies to investigate a range of conditions from Alzheimer's and heart disease to diabetes, cancer and organ rejection.
VisualSonics Contact:
Tom Little
President and CEO
VisualSonics Inc.
Toronto, Canada
Tel. 416.484.5010
Email tlittle@visualsonics.com